

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/085,056	03/01/2002	Takahiro Maruyama	220081US0	8219
22850	7590 09/09/2003	•		
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			EXAMINER	
	1940 DUKE STREET ALEXANDRIA, VA 22314		SAKELARIS, SALLY A	
			ART UNIT	PAPER NUMBER
			1634	
			DATE MAILED: 00/00/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/085,056	MARUYAMA ET AL.	
Office Action Summary	Examiner	Art Unit	
	Sally A Sakelaris	1634	
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet wit	th the correspondenc address	
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR - after SIX (6) MONTHS from the mailing date of this communication If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by state - Any reply received by the Office later than three months after the mail - earned patent term adjustment. See 37 CFR 1.704(b). Status	I. 1.136(a). In no event, however, may a re apply within the statutory minimum of thirty and will apply and will expire SIX (6) MONT ute, cause the application to become AB.	pply be timely filed (30) days will be considered timely. IHS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
1) Responsive to communication(s) filed on <u>0</u>	1 March 2002 .		
2a) ☐ This action is FINAL . 2b) ☑ -	This action is non-final.		
3) Since this application is in condition for allow closed in accordance with the practice under Disposition of Claims			
4) Claim(s) 1-8 is/are pending in the application	n.		
4a) Of the above claim(s) is/are withdr	awn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) 1-8 are subject to restriction and/or	election requirement.		
Application Papers			
9) The specification is objected to by the Examir			
10)☐ The drawing(s) filed on is/are: a)☐ acc	•		
Applicant may not request that any objection to	•	• •	
11) The proposed drawing correction filed on		sapproved by the Examiner.	
If approved, corrected drawings are required in a	• •		
12) The oath or declaration is objected to by the E	=xaminer.		
Priority under 35 U.S.C. §§ 119 and 120		442() ()	
13) Acknowledgment is made of a claim for forei	gn priority under 35 U.S.C. §	119(a)-(d) or (f).	
a) All b) Some * c) None of:			
1. Certified copies of the priority docume			
2. Certified copies of the priority document			
3. Copies of the certified copies of the pri application from the International E* See the attached detailed Office action for a list	Bureau (PCT Rule 17.2(a)).	_	
14) Acknowledgment is made of a claim for domes	stic priority under 35 U.S.C. §	§ 119(e) (to a provisional application).	
a) ☐ The translation of the foreign language p 15)☐ Acknowledgment is made of a claim for dome	• •		
Attachment(s)			
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of In	ummary (PTO-413) Paper No(s) Iformal Patent Application (PTO-152)	

Application/Control Number: 10/085,056

Art Unit: 1634

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. §121:

I. Claims 1-2 are drawn to oligonucleotides for the detection or amplification of VT1

RNA segments as classified in for example, Class 536, subclasses 23.1, 24.3, and 24.32.

II. Claims 3-8 are drawn to a process of detecting VT1 RNA as classified for example in

Class 435, subclass 6.

2. The inventions are distinct, each from the other because of the following reasons:

a. Inventions I and II are related as products and process of use. The inventions can be

shown to be distinct if either or both of the following can be shown: (1) the process for using the

product as claimed can be practiced with another materially different product or (2) the product

as claimed can be used in a materially different process of using that product (MPEP

§ 806.05(h)). In the instant case the oligonucleotides of invention I can be used in a materially

different process such as for probes comprising a microarray used for differential expression

analysis of VT1 sequences.

Restriction Requirement Applicable to All Groups:

3. Each sequence is patentably distinct because they are unrelated sequences, i.e. these

sequences are unrelated because the protein encoded by these sequences differs in structure and

in function and in biological activity. A restriction is applied to each Group. For an elected

Group drawn to a nucleotide sequence, the Applicants must elect a single pair of

oligonucleotides with which to amplify/bind the VT-1 RNA for further prosecution. An example

Page 2

Application/Control Number: 10/085,056

Art Unit: 1634

of a responsive election to this restriction requirement would be the following; if applicant elects group I for prosecution, they must further elect 1). A single oligonucleotide from SEQ ID NOS 1-5 and a single other oligonucleotide from SEQ ID NOS: 6-14. The same requirement is made for the election of Group II's process, ie one SEQ ID NO: from 1-5(or one from 6-14, or one from SEQ ID NOS: 24-25)and one from SEQ ID NOS:15-18(or 19-23). Each group can have only two elected oligonucleotides for further examination.(See MPEP 803.04).

The search of the selected sequence may include the complements of the selected sequences and, where appropriate, may include subsequences within the selected sequences (e.g., oligomeric probes and/or primers).

Nucleotide sequences with different nucleic acid sequences and containing different single nucleotide polymorphisms(SNPs) are structurally distinct chemical compounds and are unrelated to one another. Similarly, proteins comprising unique amino acid sequences are structurally and functionally distinct. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by the different classifications and their divergent subject matter and because these inventions require different searches that are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

Application/Control Number: 10/085,056

Art Unit: 1634

5. Applicant is advised that the reply to this requirement, to be complete, must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

7. Any inquiry concerning this communication or earlier communication from the examiner

should be directed to Sally Sakelaris whose telephone number is (703) 306-0284. The examiner

can normally be reached on Monday-Friday from 8:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, W.Gary Jones, can be reached on (703)308-1152. The fax number for the

Technology Center is (703)305-3014 or (703)305-4242.

Any inquiry of a general nature or relating to the status of this application should be

directed to Chantae Dessau whose telephone number is (703)605-1237.

Sally Sakelaris

9/08/03

GARY BENZION, PH.D SUPERVISORY PATENT EXAMINER

Page 4

TECHNOLOGY CENTER 1600